Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Guly

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Ocular Immunology and Inflammation|January 5, 2024
Long-Term Visual Outcome of Patients with Blau SyndromeElke O Kreps, Dalila Al Julandani, Catherine M Guly, et al.
Trials|October 10, 2021
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)Athimalaipet V Ramanan, Catherine M Guly, Stuart Y Keller, et al.
Pediatric Rheumatology Online Journal|August 8, 2018
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapyMegan Cann, Athimalaipet V Ramanan, Andrew Crawford, et al.
Survey of Ophthalmology|November 25, 2015
Managing juvenile idiopathic arthritis-associated uveitisMadeleine J Hawkins, Andrew D Dick, Richard J W Lee, et al.
Acta Ophthalmologica|September 12, 2014
Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (Blau syndrome)Ester Carreño, Catherine M Guly, Michael Chilov, et al.
American Journal of Ophthalmology|June 16, 2019
Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE TrialSarah Horton, Ashley P Jones, Catherine M Guly, et al.
The Journal of Rheumatology|October 3, 2013
The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhoodJessica A Little, Ethan S Sen, Helen Strike, et al.
Arthritis Care & Research|September 30, 2021
Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative DataKeziah Austin, Emma Dures, Celia Almeida, et al.
Lancet (London, England)|January 25, 2025
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trialNisha R Acharya, Athimalaipet V Ramanan, Alison B Coyne, et al.
American Journal of Ophthalmology|September 10, 2017
Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case SeriesInge L Sarens, Ingele Casteels, Jordi Anton, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Ocular Immunology and Inflammation|January 5, 2024
Long-Term Visual Outcome of Patients with Blau SyndromeElke O Kreps, Dalila Al Julandani, Catherine M Guly, et al.
Trials|October 10, 2021
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)Athimalaipet V Ramanan, Catherine M Guly, Stuart Y Keller, et al.
Pediatric Rheumatology Online Journal|August 8, 2018
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapyMegan Cann, Athimalaipet V Ramanan, Andrew Crawford, et al.
Survey of Ophthalmology|November 25, 2015
Managing juvenile idiopathic arthritis-associated uveitisMadeleine J Hawkins, Andrew D Dick, Richard J W Lee, et al.
Acta Ophthalmologica|September 12, 2014
Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (Blau syndrome)Ester Carreño, Catherine M Guly, Michael Chilov, et al.
American Journal of Ophthalmology|June 16, 2019
Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE TrialSarah Horton, Ashley P Jones, Catherine M Guly, et al.
The Journal of Rheumatology|October 3, 2013
The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhoodJessica A Little, Ethan S Sen, Helen Strike, et al.
Arthritis Care & Research|September 30, 2021
Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative DataKeziah Austin, Emma Dures, Celia Almeida, et al.
Lancet (London, England)|January 25, 2025
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trialNisha R Acharya, Athimalaipet V Ramanan, Alison B Coyne, et al.
American Journal of Ophthalmology|September 10, 2017
Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case SeriesInge L Sarens, Ingele Casteels, Jordi Anton, et al.
Pageof 2